Therapeutic strategies for advanced respectable esophageal cancer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

There are obvious differences in the clinical characteristics of patients with advanced respectable esophageal cancer between Japan and Western countries. In Japan, more than 90% of patients with esophageal cancer are histologically diagnosed with squamous cell carcinoma. On the other hand, the incidence of esophageal adenocarcinoma is rapidly increasing in the West. As a standard surgical approach, relatively invasive transthoracic extended esophagectomy has been established in Japan since the 1980s and has contributed to improved long-term survival of patients with squamous cell carcinoma. The current standard care for resectable stage II/III esophageal squamous cell carcinoma is neoadjuvant chemotherapy with 5-fluorouracil/cisplatin and radical esophagectomy based on the results of Japan Clinical Oncology Group trial 9907. In the West, relatively less invasive transhiatal esophagectomy with limited lymph node dissection has played a role in the multidisciplinary treatment of esophageal adenocarcinoma. Recently, a multimodal approach to esophageal cancer treatment including definitive chemoradiotherapy has been a focus of attention in both Japan and the West. For the further improvement of long-term survival of patients with esophageal cancer, the optimization of multimodal treatments and establishment of a global standard are essential.

Original languageEnglish
Pages (from-to)333-337
Number of pages5
JournalNippon Geka Gakkai zasshi
Volume109
Issue number6
Publication statusPublished - 2008 Nov

Fingerprint

Esophageal Neoplasms
Japan
Esophagectomy
Squamous Cell Carcinoma
Adenocarcinoma
Therapeutics
Combined Modality Therapy
Survival
Medical Oncology
Chemoradiotherapy
Lymph Node Excision
Fluorouracil
Cisplatin
Drug Therapy
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic strategies for advanced respectable esophageal cancer. / Kitagawa, Yuukou.

In: Nippon Geka Gakkai zasshi, Vol. 109, No. 6, 11.2008, p. 333-337.

Research output: Contribution to journalArticle

@article{2f7c50ecc1724f418dabe831d255abd7,
title = "Therapeutic strategies for advanced respectable esophageal cancer",
abstract = "There are obvious differences in the clinical characteristics of patients with advanced respectable esophageal cancer between Japan and Western countries. In Japan, more than 90{\%} of patients with esophageal cancer are histologically diagnosed with squamous cell carcinoma. On the other hand, the incidence of esophageal adenocarcinoma is rapidly increasing in the West. As a standard surgical approach, relatively invasive transthoracic extended esophagectomy has been established in Japan since the 1980s and has contributed to improved long-term survival of patients with squamous cell carcinoma. The current standard care for resectable stage II/III esophageal squamous cell carcinoma is neoadjuvant chemotherapy with 5-fluorouracil/cisplatin and radical esophagectomy based on the results of Japan Clinical Oncology Group trial 9907. In the West, relatively less invasive transhiatal esophagectomy with limited lymph node dissection has played a role in the multidisciplinary treatment of esophageal adenocarcinoma. Recently, a multimodal approach to esophageal cancer treatment including definitive chemoradiotherapy has been a focus of attention in both Japan and the West. For the further improvement of long-term survival of patients with esophageal cancer, the optimization of multimodal treatments and establishment of a global standard are essential.",
author = "Yuukou Kitagawa",
year = "2008",
month = "11",
language = "English",
volume = "109",
pages = "333--337",
journal = "Nihon Geka Gakkai zasshi",
issn = "0301-4894",
publisher = "Nihon Geka Gakkai",
number = "6",

}

TY - JOUR

T1 - Therapeutic strategies for advanced respectable esophageal cancer

AU - Kitagawa, Yuukou

PY - 2008/11

Y1 - 2008/11

N2 - There are obvious differences in the clinical characteristics of patients with advanced respectable esophageal cancer between Japan and Western countries. In Japan, more than 90% of patients with esophageal cancer are histologically diagnosed with squamous cell carcinoma. On the other hand, the incidence of esophageal adenocarcinoma is rapidly increasing in the West. As a standard surgical approach, relatively invasive transthoracic extended esophagectomy has been established in Japan since the 1980s and has contributed to improved long-term survival of patients with squamous cell carcinoma. The current standard care for resectable stage II/III esophageal squamous cell carcinoma is neoadjuvant chemotherapy with 5-fluorouracil/cisplatin and radical esophagectomy based on the results of Japan Clinical Oncology Group trial 9907. In the West, relatively less invasive transhiatal esophagectomy with limited lymph node dissection has played a role in the multidisciplinary treatment of esophageal adenocarcinoma. Recently, a multimodal approach to esophageal cancer treatment including definitive chemoradiotherapy has been a focus of attention in both Japan and the West. For the further improvement of long-term survival of patients with esophageal cancer, the optimization of multimodal treatments and establishment of a global standard are essential.

AB - There are obvious differences in the clinical characteristics of patients with advanced respectable esophageal cancer between Japan and Western countries. In Japan, more than 90% of patients with esophageal cancer are histologically diagnosed with squamous cell carcinoma. On the other hand, the incidence of esophageal adenocarcinoma is rapidly increasing in the West. As a standard surgical approach, relatively invasive transthoracic extended esophagectomy has been established in Japan since the 1980s and has contributed to improved long-term survival of patients with squamous cell carcinoma. The current standard care for resectable stage II/III esophageal squamous cell carcinoma is neoadjuvant chemotherapy with 5-fluorouracil/cisplatin and radical esophagectomy based on the results of Japan Clinical Oncology Group trial 9907. In the West, relatively less invasive transhiatal esophagectomy with limited lymph node dissection has played a role in the multidisciplinary treatment of esophageal adenocarcinoma. Recently, a multimodal approach to esophageal cancer treatment including definitive chemoradiotherapy has been a focus of attention in both Japan and the West. For the further improvement of long-term survival of patients with esophageal cancer, the optimization of multimodal treatments and establishment of a global standard are essential.

UR - http://www.scopus.com/inward/record.url?scp=58149382612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149382612&partnerID=8YFLogxK

M3 - Article

VL - 109

SP - 333

EP - 337

JO - Nihon Geka Gakkai zasshi

JF - Nihon Geka Gakkai zasshi

SN - 0301-4894

IS - 6

ER -